• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » EarlySense wins FDA clearance for patient monitoring system

EarlySense wins FDA clearance for patient monitoring system

June 21, 2010 By MedCity News

MedCity News logo

By Mary Vanac

Ramat Gan, Israel-based medical device company EarlySense Ltd., which recently closed a $13 million fund-raising round, received Food & Drug Administration clearance to sell its EverOn Touch patient monitoring system in the United States.

EverOn is a patient supervision system that goes underneath a hospital bed mattress. The device measures patients’ vital signs, such as heart and respiration rates, as well as movements to alert caregivers about their medical condition.

The Touch version of the product includes an online display that alerts medical staff about a patient’s motion level and verifies patient turns by nurses, the company said in a press release. Identifying low patient movement and then turning patients methodically can prevent pressure ulcers, one of the most costly patient safety risk in U.S. hospitals.

“Today’s FDA clearance news further validates our technology,” said Avner Halperin, EarlySense chief executive, in the release. “We have repeatedly heard from our partner hospitals that preventing pressure ulcers is a critical need due to the enormous burden pressure ulcers place on hospital budgets and the huge task of preventing them. The addition of pressure ulcer prevention support capabilities to a system that already delivers vital sign detection and bed exit alerts further enhances the EverOn as a full contact-free patient safety suite for hospitalized patients.”

Clinical evaluations performed worldwide showed EverOn has significantly improved clinical and economic outcomes for hospitals using the system, the company said.

“The EverOn Touch system incorporates feedback we have received from our clinical sites requesting a more convenient touch screen interface, as well as more comprehensive patient motion monitoring, especially as it relates to patients at risk of pressure ulcers and falls,” said EarlySense vice president of clinical and regulatory affairs Dalia Argaman in the release. “The FDA clearance strengthens our belief that EverOn will make a positive impact on the future of clinical practice and improve patient care both at the hospital and in post acute care settings.”

In early June, EarlySense raised $13 million from mostly Israeli investment firms to launch its improved monitoring system in the United States and Europe. Bridge Investment Fund in Cleveland, Ohio, also is an investor and participated in the recent fund-raising round.

The company last year received a grant from the Global Cardiovascular Innovation Center led by the Cleveland Clinic. At that time, EarlySense said it planned to establish a base of operations in the Cleveland area to develop the next version of its patient-monitoring device. “We have not opened an office yet,” Halperin said through a spokeswoman early this month. “We are now in the hiring process, and we are looking at several options regarding locations in the USA.”

EarlySense has an office in Dedham, Massachusetts.

Filed Under: Business/Financial News, News Well Tagged With: EarlySense

More recent news

  • Former Intuitive sales leader joins surgical robot maker Virtual Incision as CEO
  • Smith+Nephew to open first orthopedic ambulatory surgery center in the UK
  • Medtronic partners with IRCAD on Hugo, Affera surgical training
  • 23andMe co-founder wins bid to take back control of company
  • Neurent Medical opens new manufacturing facility in Ireland

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy